

# Catia Giovannini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8092866/publications.pdf>

Version: 2024-02-01

38  
papers

3,665  
citations

331670

21  
h-index

315739

38  
g-index

40  
all docs

40  
docs citations

40  
times ranked

5419  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma. <i>Cancer Research</i> , 2007, 67, 6092-6099.	0.9	782
2	IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. <i>Journal of Clinical Investigation</i> , 2007, 117, 3988-4002.	8.2	682
3	MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. <i>Oncogene</i> , 2008, 27, 5651-5661.	5.9	619
4	MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. <i>Cancer Research</i> , 2009, 69, 5761-5767.	0.9	380
5	p66Shc/Notch-3 Interplay Controls Self-Renewal and Hypoxia Survival in Human Stem/Progenitor Cells of the Mammary Gland Expanded In Vitro as Mammospheres. <i>Stem Cells</i> , 2007, 25, 807-815.	3.2	171
6	In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis. <i>Clinical Cancer Research</i> , 2017, 23, 3953-3965.	7.0	137
7	Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma. <i>Liver International</i> , 2007, 27, 997-1007.	3.9	96
8	Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. <i>Journal of Hepatology</i> , 2009, 50, 969-979.	3.7	87
9	The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2018, 9, 4.	6.3	68
10	CDKN1C/P57 Is Regulated by the Notch Target Gene Hes1 and Induces Senescence in Human Hepatocellular Carcinoma. <i>American Journal of Pathology</i> , 2012, 181, 413-422.	3.8	58
11	MiR-30e-3p Influences Tumor Phenotype through MDM2/TP53 Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2020, 80, 1720-1734.	0.9	47
12	LncRNAs as novel players in hepatocellular carcinoma recurrence. <i>Oncotarget</i> , 2018, 9, 35085-35099.	1.8	46
13	Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3 $\beta$ phosphorylation and p21 down-regulation in hepatocellular carcinoma. <i>Oncotarget</i> , 2013, 4, 1618-1631.	1.8	42
14	Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2018, 155, 839-846.	5.5	41
15	In human hepatocellular carcinoma in cirrhosis proliferating cell nuclear antigen (PCNA) is involved in cell proliferation and cooperates with P21 in DNA repair. <i>Journal of Hepatology</i> , 2003, 39, 997-1003.	3.7	40
16	Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. <i>Oncotarget</i> , 2014, 5, 10607-10620.	1.8	39
17	Targeting Notch3 in Hepatocellular Carcinoma: Molecular Mechanisms and Therapeutic Perspectives. <i>International Journal of Molecular Sciences</i> , 2017, 18, 56.	4.1	35
18	GADD45 $\beta$ expression in cirrhosis and hepatocellular carcinoma: relationship with DNA repair and proliferation. <i>Human Pathology</i> , 2005, 36, 1154-1162.	2.0	31

#	ARTICLE	IF	CITATIONS
19	Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 741-757.	3.7	29
20	Notch3 intracellular domain accumulates in HepG2 cell line. <i>Anticancer Research</i> , 2006, 26, 2123-7.	1.1	29
21	MicroRNAs in Animal Models of HCC. <i>Cancers</i> , 2019, 11, 1906.	3.7	25
22	Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 39609-39626.	1.8	25
23	MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma. <i>Acta Histochemica</i> , 2018, 120, 95-102.	1.8	22
24	Human hepatocellular carcinoma expresses specific PCNA isoforms: an in vivo and in vitro evaluation. <i>Laboratory Investigation</i> , 2008, 88, 995-1007.	3.7	21
25	Molecules Present in Plant Essential Oils for Prevention and Treatment of Colorectal Cancer (CRC). <i>Molecules</i> , 2021, 26, 885.	3.8	20
26	Direct Antiviral Treatments for Hepatitis C Virus Have Off-Target Effects of Oncologic Relevance in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2674.	3.7	13
27	Notch Signaling Regulation in HCC: From Hepatitis Virus to Non-Coding RNAs. <i>Cells</i> , 2021, 10, 521.	4.1	13
28	MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 369-385.	3.7	12
29	Telomerase Activity in Touch&ndash;Imprint Cell Preparations from Fresh Prostate Needle Biopsy Specimens. <i>European Urology</i> , 2001, 40, 666-672.	1.9	11
30	Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma. <i>Scientific Reports</i> , 2017, 7, 44685.	3.3	11
31	Brivanib in combination with Notch3 silencing shows potent activity in tumour models. <i>British Journal of Cancer</i> , 2019, 120, 601-611.	6.4	7
32	Hepatic Cancer Stem Cells: Molecular Mechanisms, Therapeutic Implications, and Circulating Biomarkers. <i>Cancers</i> , 2021, 13, 4550.	3.7	6
33	Fast and real-time electrical transistor assay for quantifying SARS-CoV-2 neutralizing antibodies. <i>Communications Materials</i> , 2022, 3, .	6.9	6
34	Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area. <i>Nutrients</i> , 2022, 14, 1652.	4.1	6
35	FIBROUS HAMARTOMA OF CORPUS CAVERNOSUM: A RARE CAUSE OF CONGENITAL PENILE CURVATURE ASSOCIATED WITH ERECTILE DYSFUNCTION. <i>Journal of Urology</i> , 2004, 172, 642-643.	0.4	3
36	Organic Electrochemical Transistors as Versatile Tool for Real-Time and Automatized Viral Cytopathic Effect Evaluation. <i>Viruses</i> , 2022, 14, 1155.	3.3	2

#	ARTICLE	IF	CITATIONS
37	MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma. <i>Biomolecules</i> , 2022, 12, 930.	4.0	2
38	Improved sorafenib activity on hepatocellular carcinoma in Notch3 silenced in vivo and in vitro models.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3061-3061.	1.6	0